Department of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
Int J Mol Sci. 2022 Dec 16;23(24):16084. doi: 10.3390/ijms232416084.
Introduction-Recovery from peripheral nerve injuries is poor even though injured peripheral axons can regenerate. Novel therapeutic approaches are needed. The most successful preclinical experimental treatments have relied on increasing the activity of the regenerating axons, but the approaches taken are not applicable to many nerve-injured patients. Bioluminescent optogenetics (BL-OG) is a novel method of increasing the excitation of neurons that might be similar to that found with activity-dependent experimental therapies. We investigated the use of BL-OG as an approach to promoting axon regeneration following peripheral nerve injury. Methods-BL-OG uses luminopsins, light-sensing ion channels (opsins) fused with a light-emitting luciferase. When exposed to a luciferase substrate, such as coelenterazine (CTZ), luminopsins expressed in neurons generate bioluminescence and produce excitation through their opsin component. Adeno-associated viral vectors encoding either an excitatory luminopsin (eLMO3) or a mutated form (R115A) that can generate bioluminescence but not excite neurons were injected into mouse sciatic nerves. After retrograde transport and viral transduction, nerves were cut and repaired by simple end-to-end anastomosis, and mice were treated with a single dose of CTZ. Results-Four weeks after nerve injury, compound muscle action potentials (M waves) recorded in response to sciatic nerve stimulation were more than fourfold larger in mice expressing the excitatory luminopsin than in controls expressing the mutant luminopsin. The number of motor and sensory neurons retrogradely labeled from reinnervated muscles in mice expressing eLMO3 was significantly greater than the number in mice expressing the R115A luminopsin and not significantly different from those in intact mice. When viral injection was delayed so that luminopsin expression was induced after nerve injury, a clinically relevant scenario, evoked M waves recorded from reinnervated muscles were significantly larger after injury in eLMO3-expressing mice. Conclusions-Treatment of peripheral nerve injuries using BL-OG has significant potential to enhance axon regeneration and promote functional recovery.
简介-尽管受损的周围神经轴突可以再生,但周围神经损伤的恢复情况仍不理想。因此,需要新的治疗方法。最成功的临床前实验治疗方法依赖于增加再生轴突的活性,但这些方法并不适用于许多神经损伤患者。生物发光光遗传学(BL-OG)是一种增加神经元兴奋的新方法,其效果可能类似于基于活性的实验治疗方法。我们研究了 BL-OG 在促进周围神经损伤后轴突再生中的应用。方法-BL-OG 使用的是发光蛋白,即与发光酶融合的光感离子通道(视蛋白)。当暴露于发光酶的底物,如腔肠素(CTZ)时,神经元中表达的发光蛋白会产生生物发光,并通过其视蛋白成分产生兴奋。表达兴奋性发光蛋白(eLMO3)或可产生生物发光但不能兴奋神经元的突变体(R115A)的腺相关病毒载体被注射到小鼠坐骨神经中。在逆行转运和病毒转导后,切断神经并通过简单的端端吻合修复,然后用单剂量 CTZ 处理小鼠。结果-在神经损伤后 4 周,用坐骨神经刺激记录的复合肌肉动作电位(M 波)在表达兴奋性发光蛋白的小鼠中比在表达突变体发光蛋白的对照组中大 4 倍以上。表达 eLMO3 的小鼠中重新支配肌肉的运动和感觉神经元的逆行标记数量明显多于表达 R115A 发光蛋白的小鼠,与正常小鼠无显著差异。当延迟病毒注射,使发光蛋白在神经损伤后表达时,在 eLMO3 表达小鼠中,损伤后记录到的诱发 M 波明显更大。结论-BL-OG 治疗周围神经损伤具有显著增强轴突再生和促进功能恢复的潜力。